Aging and immunotherapies: New horizons for the golden ages.
Aging and immunotherapies: New horizons for the golden ages.
复制标题
DOI：
10.1002/aac2.12014
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Henry, Curtis J
中科院分区：
文献类型：
--
作者：
Hamilton, Jamie A G;Henry, Curtis J
世界老年人口（65 岁及以上）的预期寿命继续达到新的里程碑，目前老年人占世界人口的 8.5% 以上（6.17 亿）。预计到 2050 年，这一比例将接近世界人口的 20%（即 16 亿人）。尽管取得了这一惊人的成就，但许多医疗保健系统没有能力处理通常随年龄增长而出现的多种疾病，包括大多数类型的癌症。随着世界人口老龄化的增长，癌症治疗方法不断发展。免疫疗法是一种新的药物类别，它彻底改变了我们治疗以前难治性癌症的能力；然而，它们对免疫系统受损患者的疗效仍不清楚。在这篇综述中，我们将讨论与衰老相关的免疫稳态丧失如何影响临床前衰老模型中免疫疗法的疗效和安全性。我们还将讨论这些发现如何转化为接受免疫疗法治疗难治性和复发性癌症的老年患者，以及可以探索提高老年患者免疫疗法疗效的策略。
The life expectancy of the world’s elderly population (65 and older) continues to reach new milestones with older individuals currently comprising greater than 8.5% (617 million) of the world’s population. This percentage is predicted to approach 20% of the world’s population by 2050 (representing 1.6 billion people). Despite this amazing feat, many healthcare systems are not equipped to handle the multitude of diseases that commonly manifest with age, including most types of cancers. As the world’s aging population grows, cancer treatments continue to evolve. Immunotherapies are a new drug class that has revolutionized our ability to treat previously intractable cancers; however, their efficacy in patients with compromised immune systems remains unclear. In this review, we will discuss how aging-associated losses in immune homeostasis impact the efficacy and safety of immunotherapy treatment in preclinical models of aging. We will also discuss how these findings translate to elderly patients receiving immunotherapy treatment for refractory and relapsed cancers, as well as, strategies that could be explored to improve the efficacy of immunotherapies in aged patients.